Table 2 Linear and multivariate analysis of relationship between post-bronchodilator FEV1 % predicted and sputum neutrophil percentage at the baseline visit.
From: Sputum neutrophils as a biomarker in COPD: findings from the ECLIPSE study
| Â | Linear Regression | Â | Multiple Regression | ||||
|---|---|---|---|---|---|---|---|
Independent Variables in Model | Estimate(SE) | p-value | R-square | Â | Estimate(SE) | p-value | R-square |
Age | 0.095 (0.119) | 0.425 | 0.002 | Â | 0.197 (0.118) | 0.097 | 0.139 |
BMI | 0.341 (0.141) | 0.016 | 0.016 | Â | 0.381 (0.140) | 0.007 | Â |
Concomitant ICS use | 5.047 (1.873) | 0.007 | 0.020 | Â | 6.759 (1.806) | <0.001 | Â |
Current smoking status | 1.216 (1.658) | 0.464 | 0.002 | Â | 1.255 (1.689) | 0.458 | Â |
Pack years | -0.015 (0.029) | 0.602 | 0.001 | Â | 0.001 (0.029) | 0.976 | Â |
Gender | 7.904 (1.636) | <0.001 | 0.061 | Â | 8.785 (1.634) | <0.001 | Â |
Sputum neutrophil % | -0.147 (0.049) | 0.003 | 0.025 | Â | -0.127 (0.048) | 0.009 | Â |